You are here

TLR5 Antagonists for Infectious Disease Therapy

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI072912-01
Agency Tracking Number: AI072912
Amount: $300,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: 2007
Award Year: 2007
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
MICROBIOTIX, INC ONE INNOVATION DR
WORCESTER, MA 01605
United States
DUNS: 158864715
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 STEPHEN LORY
 (617) 432-5099
 STEPHEN_LORY@HMS.HARVARD.EDU
Business Contact
Phone: (508) 757-2800
Email: tbowlin@microbiotix.com
Research Institution
 HARVARD MEDICAL SCHOOL
 
HARVARD UNIVERSITY MEDICAL SCHOOL CAMPUS
BOSTON, MA 2115
United States

 Nonprofit College or University
Abstract

DESCRIPTION (provided by applicant): A family of conserved toll-like receptors (TLRs) found on a variety of human cell types plays an important role in recognition of invading pathogens and in mounting an effective inflammatory immune response. Each these receptors binds a specific microbial ligand and triggers a signal transduction pathway leading to transcription of genes encoding pro-inflammatory cytokines, chemokines and variety of innate host-defense molecules . Activation of TLRs is critical for mobilization of the innate immune response, an early acting protective mechanism for the human host during many bacterial infections. Surprisingly, however, the same signaling pathways can be detrimental to the host and exacerbate the infection, causing extensive tissue destruction and bacterial dissemination by provoking excessive and damaging inflammation. This occurs in certain acute and chronic infections, including Pseudomonas aeruginosa and Burkholderia cepacia infections in cystic fibrosis as well as P. aeruginosa and B. pseudomallei infections in pneumonia and septicemia. One such TLR ligand is flagellin, a component of the bacterial flagellar motility apparatus, which is recognized by TLR5. In preliminary studies, this flagellin-TLR5 interaction was shown to be the major cause of Pseudomonas aeruginosa virulence, survival, and dissemination in a mouse pneumonia model. The overall objective of this research is to develop therapeutic agents that antagonize the pro-inflammatory signaling pathways resulting from the interaction between TLR5 and flagellin. In Phase I, a sensitive whole-cell assay will be applied to screen libraries of compounds for antagonists of flagellin/TLR5 interaction. Following confirmation of the hits from the high throughput screen, the active compounds will be characterized in secondary assays to identify those which are non-toxic and which specifically interfere with the flagellin-TLR5 signaling pathway. The most potent, specific, inhibitors will be tested in a P. aeruginosa infection model, in which lung colonization and dissemination into organs depends on the expression of flagellin by this organism. The results of this Phase I project will provide in vivo validated TLR5 antagonists for the development of therapeutics to reduce morbidity and mortality in bacterial sepsis and chronic infections.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government